BICX SEC-arkiveringar - BioCorRx Inc.- Årsredovisning, Fullmaktsutlåtande, prospekt

Grundläggande statistik

CIK

1443863

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BioCorRx Inc.

SEC Filings (Chronological Order)

Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.

August 14, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54208 BioCorRx Inc. (Exac
August 1, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 29, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 29, 2025 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or other jurisdiction of incorporation) (Commission File Number)
August 1, 2025	EX-4.1	Form of Warrant EXHIBIT 4.1 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION TH
August 1, 2025	EX-10.1	Form of Securities Purchase Agreement, dated July 29, 2025 EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of July 29, 2025, is entered into by and between BioCorRx Inc., a Nevada corporation, (the “Company”) and the investors listed on Exhibit A attached to this Agreement (each a “Purchaser” and together the “Purchasers”). WHEREAS, the Company desires to issue and sell to and each Purchaser desir
May 15, 2025	EX-10.1	Director Agreement with Kate Beebe DeVarney, Ph.D. EXHIBIT 10.1 DIRECTOR AGREEMENT This DIRECTOR AGREEMENT is entered into as of March 04, 2025 (the “Agreement”), by and between BioCorRx Inc., a Nevada corporation with an address of 2390 E Orangewood Ave, Ste 570, Anaheim, CA 92806 (the “Company”), and Kate Beebe DeVarney, Ph.D., an individual with an address of [ ] (the “Director”). WHEREAS, the Company desires to appoint Kate Beebe DeVarney to s
May 15, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54208 BioCorRx Inc. (Exa
March 31, 2025	EX-19.1	Insider Trading Policy EXHIBIT 19.1 BIOCORRX INC. POLICY ON INSIDER TRADING This Insider Trading Policy (“Policy”) sets forth the policies of BioCorRx Inc. (the “Company”) on trading and causing the trading of securities while in possession of confidential information. Purpose The Board of Directors of the Company has adopted this Policy to provide guidance to the Company’s directors, officers, and employees about tradi
March 31, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 Commission File Number: 000-54208 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 Commission File Number: 000-54208 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 90-0967447 (State or other jurisdiction of incorporation or organization) (IRS
March 31, 2025	EX-14.1	Code of Business Conduct and Ethics EXHIBIT 14.1 CODE OF ETHICS OF BIOCORRX INC. 1. Introduction The Board of Directors of BioCorRx Inc. (the “Company”) has adopted this code of ethics (the “Code”), which is applicable to all directors, officers and employees of the Company, with the intent to: · promote honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and profes
March 11, 2025	EX-10.2	Securities Purchase Agreement by and between BioCorRx Inc. and USWM, LLC, dated March 4, 2025 EXHIBIT 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of March 4, 2025, is entered into by and between BioCorRx Inc., a Nevada corporation, (the “Company”) and USWM, LLC, a Delaware limited liability company (“USWM”). A. The Company, the Company’s majority owned subsidiary, BioCorRx Pharmaceuticals, Inc., a Nevada corporation (the “Subsidiary”)
March 11, 2025	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 4, 2025 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or other jurisdiction of incorporation) (Commission File Number)
March 11, 2025	EX-4.1	Form of Warrant EXHIBIT 4.1 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION TH
March 11, 2025	EX-10.1	Asset Purchase Agreement by and among BioCorRx Pharmaceuticals, Inc., BioCorRx Inc., and USWM, LLC, dated March 4, 2025 EXHIBIT 10.1 ASSET PURCHASE AGREEMENT This ASSET PURCHASE AGREEMENT, dated as of March 4, 2025 (the “Agreement”), between BioCorRx Pharmaceuticals, Inc., a Nevada corporation (“Buyer”), a majority-owned subsidiary of BioCorRx Inc. (as more specifically described herein, “Buyer’s Parent”), and USWM, LLC, a Delaware limited liability company (“Seller”). RECITALS A. Seller is engaged in the business
March 11, 2025	EX-99.1	BioCorRx Pharmaceuticals Inc. announces that it has acquired LUCEMYRA® (lofexidine), an FDA-Approved Opioid Withdrawal Medication, from USWM, LLC EXHIBIT 99.1 BioCorRx Pharmaceuticals Inc. announces that it has acquired LUCEMYRA® (lofexidine), an FDA-Approved Opioid Withdrawal Medication, from USWM, LLC ANAHEIM, CA & Louisville, KY, March 10, 2025 – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders and USWM LLC, a specialty pharmaceutical company
November 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54208 BioCorRx Inc.
August 13, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54208 BioCorRx Inc. (Exac
July 10, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 8, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 8, 2024 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or other jurisdiction of incorporation) (Commission File Number) (
July 10, 2024	EX-16.1	Letter from Marcum LLP to the Securities and Exchange Commission EXHIBIT 16.1 July 9, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by BioCorRx, Inc. under Item 4.01 of its Form 8-K dated July 8, 2024. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of BioCorRx, Inc. contained therein. Very trul
May 15, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54208 BioCorRx Inc. (Exa
April 3, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 29, 2024 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or other jurisdiction of incorporation) (Commission File Number)
April 1, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 Commission File Number: 000-54208 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 Commission File Number: 000-54208 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 90-0967447 (State or other jurisdiction of incorporation or organization) (IRS
January 5, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 29, 2023 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or other jurisdiction of incorporation) (Commission File Numb
January 5, 2024	EX-10.1	Executive Service Agreement with Louis Lucido, dated January 5, 2024 EXHIBIT 10.1 EXECUTIVE SERVICE AGREEMENT THIS EXECUTIVE SERVICE AGREEMENT dated as of January 5, 2024 (the “Agreement”) is by and between BioCorRx Inc., a Nevada corporation (the “Company”), and Louis Lucido (the “Executive”). WHEREAS, the Company is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. Beat Addiction Rec
December 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 8, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 8, 2023 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or other jurisdiction of incorporation) (Commission File Numbe
December 15, 2023	EX-10.2	Form of Promissory Note EXHIBIT 10.2 NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSU
December 15, 2023	EX-4.1	Form of Warrant EXHIBIT 4.1 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT OR APPLICABLE EXEMPTION OR SAFE HARBOR PROVISION. COMMON STOCK PURCHAS
December 15, 2023	EX-10.1	Securities Purchase Agreement by and between BioCorRx Inc. and Investor, dated December 8, 2023 EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of December 08, 2023, is entered into by and between BioCorRx Inc., a Nevada corporation, (the “Company”), and (the “Buyer”). A. The Company and the Buyer are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by the rules and regulati
November 16, 2023	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 10, 2023 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or other jurisdiction of incorporation) (Commission File Numb
November 16, 2023	EX-4.1	Form of Warrant EXHIBIT 4.1 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT OR APPLICABLE EXEMPTION OR SAFE HARBOR PROVISION. COMMON STOCK PURCHAS
November 16, 2023	EX-10.2	Form of Promissory Note EXHIBIT 10.2 NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSU
November 16, 2023	EX-10.1	Securities Purchase Agreement by and between BioCorRx Inc. and LGH Investments, LLC, dated November 10, 2023 EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of November 10, 2023, is entered into by and between BioCorRx Inc., a Nevada corporation, (the “Company”), and LGH Investments, LLC, a Wyoming limited liability company (the “Buyer”). A. The Company and the Buyer are executing and delivering this Agreement in reliance upon the exemption from
November 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54208 BioCorRx Inc.
November 2, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): October 30, 2023 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or other jurisdiction of incorporation) (Commission File Numbe
August 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q(Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54208 BioCorRx Inc. (Exact
May 15, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54208 BioCorRx Inc. (Exa
April 11, 2023	EX-10.1	Form of Subscription Agreement by and between BioCorRx Inc. and the Investor EXHIBIT 10.1 BioCorRx Inc. 2390 East Orangewood Avenue Suite 500 Anaheim, California 92806 The undersigned understands that BioCorRx Inc., a corporation organized under the laws of Nevada (the “Company”), desired to: (i) sell shares of its common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $1.72 per share (based on the average of the closing price for the last 20
April 11, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 4, 2023 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or other jurisdiction of incorporation) (Commission File Number)
April 11, 2023	EX-4.1	Form of Warrant EXHIBIT 4.1 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION TH
April 5, 2023	EX-10.2	Form of Exchange Agreement EXHIBIT 10.2 EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT, is dated as of April 03, 2023 (this “Agreement”), by and among BioCorRx Inc., a Nevada corporation (the “Company”) and, (the “Holder”). WHEREAS, the Holder is the holder of (i) Exhibit A; describe other securities being exchanged for shares of common stock; WHEREAS, the Company and Holder have agreed pursuant hereto to an exchange of the Pro
April 5, 2023	EX-10.1	Form of Subscription Agreement by and between BioCorRx Inc. and each of the Lucido and Galligan Trusts initially effective March 30, 2023 EXHIBIT 10.1 BioCorRx Inc. 2390 East Orangewood Avenue Suite 500 Anaheim, California 92806 The undersigned understands that BioCorRx Inc., a corporation organized under the laws of Nevada (the “Company”), desired to: (i) sell shares of its common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $1.75 per share (based on the average of the closing price for the last 20
April 5, 2023	EX-4.1	Form of Warrant (incorporated by reference to Exhibit 4.1 on the Company’s Current Report on Form 8-K filed with the SEC on April 5, 2023) EXHIBIT 4.1 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION TH
April 5, 2023	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 30, 2023 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or other jurisdiction of incorporation) (Commission File Number)
March 31, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 Commission File Number: 000-54208 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 Commission File Number: 000-54208 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 90-0967447 (State or other jurisdiction of incorporation or organization) (IRS
March 31, 2023	EX-10.15	Inter-Company License Agreement by and between BioCorRx Inc. and BioCorRx Pharmaceuticals, Inc., effective September 2, 2021 EXHIBIT 10.15 INTER-COMPANY LICENSE AGREEMENT This INTER-COMPANY LICENSE AGREEMENT (this “Agreement”) is entered into as of September 2, 2021, by and between BioCorRx Inc, a corporation organized and existing under the laws of the State of Nevada (“Licensor”), and BioCorRx Pharmaceuticals Inc, a corporation organized and existing under the laws of the State of Nevada (“Licensee” and, together with
March 31, 2023	EX-4.3	Description of securities registered under Section 12 of the Exchange Act of 1934 EXHIBIT 4.3 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Set forth below is the description of the common stock, par value $0.001 per share (the “Common Stock”) of BioCorRx Inc. (“we” or “our”). The following description summarizes the most important terms of these securities. This summary does not purport to be complete and is qua
January 23, 2023	EX-10.1	Form of Murthy Director Agreement EXHIBIT 10.1 DIRECTOR AGREEMENT This DIRECTOR AGREEMENT is entered into as of January 20, 2023 (the “Agreement”), by and between BioCorRx Inc., a Nevada corporation (the “Company”), and Harsha Murthy, an individual with an address of the “Director”). WHEREAS, the Company desires to appoint Harsha Murthy to serve as a member of the Board of Directors of the Company and desires to enter into an agre
January 23, 2023	EX-10.2	Form of Indemnification Agreement EXHIBIT 10.2 BIOCORRX INC. DIRECTOR AND OFFICER INDEMNIFICATION AGREEMENT This Director and Officer Indemnification Agreement, dated as of January 20, 2023 (the “Agreement”), is made by and between BioCorRx Inc., a Nevada corporation (the “Company”), and Harsha Murthy (the “Indemnitee”). RECITALS: A. Nevada Revised Statutes Chapter 78 provides that the business and affairs of a corporation shall b
January 23, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 20, 2023 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or other jurisdiction of incorporation) (Commission File Numbe
November 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54208 BioCorRx Inc.
November 14, 2022	EX-10.1	Form of Exchange Agreement entered into with Messrs. Galligan and Lucido in Sept 2022** EXHIBIT 10.1 EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT, is dated as of September 21, 2022 (this ?Agreement?), by and among BioCorRx Inc., a Nevada corporation (the ?Company?) and, (the ?Holder?). WHEREAS, the Holder is the holder of (i) Exhibit A; and (ii) Exhibit B; describe other securities being exchanged for shares of common stock; WHEREAS, the Company and Holder have agreed pursuant hereto t
October 27, 2022	EX-16.1	Letter to Securities and Exchange Commission from Friedman LLP, dated October 27, 2022 EXHIBIT 16.1 October 27, 2022 Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Commissioners: We have read the statements made by BioCorRx Inc. under Item 4.01 of its Form 8-K dated October 27, 2022. We agree with the statements concerning our firm in such Form 8-K; we are not in a position to agree or disagree with other statements of BioCorRx Inc contained therein. Very
October 27, 2022	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): October 21, 2022 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or other jurisdiction of incorporation) (Commission File Numbe
August 15, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54208 BioCorRx Inc. (Exac
June 10, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or other jurisdiction of incorporation) (Commission File Number) (
May 16, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54208 BioCorRx Inc. (Exa
May 12, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 6, 2022 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or other jurisdiction of incorporation) (Commission File Number) (I
May 12, 2022	EX-10.1	Form of Subscription Agreement by and between BioCorRx Inc. and the Purchaser initially effective May 6, 2022 EXHIBIT 10.1 BioCorRx Inc. 2390 East Orangewood Avenue Suite 500 Anaheim, California 92806 The undersigned understands that BioCorRx Inc., a corporation organized under the laws of Nevada (the ?Company?), desired to: (i) sell shares of its common stock, par value $0.001 per share (the ?Securities?), at a purchase price of $2.26 per share (the ?Purchase Price?); and (ii) one warrant to purchase one
May 12, 2022	EX-4.1	Form of Warrant to purchase Common Stock, dated May 5, 2022 EXHIBIT 4.1 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION TH
April 28, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 22, 2022 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or other jurisdiction of incorporation) (Commission File Number)
April 28, 2022	EX-10.1	BioCorRx Inc. 2022 Omnibus Securities and Incentive Plan EXHIBIT 10.1 BIOCORRX, INC. 2022 OMNIBUS SECURITIES AND INCENTIVE PLAN 695,000 SHARES OF COMMON STOCK Table of Contents Page ARTICLE I PURPOSE 1 ARTICLE II DEFINITIONS. 1 ARTICLE III EFFECTIVE DATE OF PLAN 4 ARTICLE IV ADMINISTRATION 4 Section 4.1 Administration Section 4.2 Powers Section 4.3 Additional Powers Section 4.4 Delegation Section 4.5 Power and Authority of the Board ARTICLE V SHARES SUB
March 31, 2022	EX-10.15	Inter-Company License Agreement by and between BioCorRx Inc. and BioCorRx Pharmaceuticals, Inc., effective September 22, 2021 EXHIBIT 10.15 INTER-COMPANY LICENSE AGREEMENT This INTER-COMPANY LICENSE AGREEMENT (this ?Agreement?) is entered into as of September 2, 2021, by and between BioCorRx Inc, a corporation organized and existing under the laws of the State of Nevada (?Licensor?), and BioCorRx Pharmaceuticals Inc, a corporation organized and existing under the laws of the State of Nevada (?Licensee? and, together with
March 31, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 Commission File Number: 000-54208 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 Commission File Number: 000-54208 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 90-0967447 (State or other jurisdiction of incorporation or organization) (IRS
March 31, 2022	EX-4.3	Description of securities registered under Section 12 of the Exchange Act of 1934 EXHIBIT 4.3 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Set forth below is the description of the common stock, par value $0.001 per share (the ?Common Stock?) of BioCorRx Inc. (?we? or ?our?). The following description summarizes the most important terms of these securities. This summary does not purport to be complete and is qua
January 19, 2022	EX-10.1	Form of Subscription Agreement by and between BioCorRx Inc. and each of the Lucido and Galligan Trusts initially effective January 12, 2022 EX-10.1 2 bicxex101.htm FORM OF SUBSCRIPTION AGREEMENT EXHIBIT 10.1 BioCorRx Inc. 2390 East Orangewood Avenue Suite 500 Anaheim, California 92806 The undersigned understands that BioCorRx Inc., a corporation organized under the laws of Nevada (the “Company”), desired to sell shares of its common stock, par value $0.001 per share (the “Securities”), at a purchase price of $4.35 per share (the “Purc
January 19, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 12, 2022 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or other jurisdiction of incorporation) (Commission File Numbe
November 15, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54208 BioCorRx Inc.
September 2, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2021 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or other jurisdiction of incorporation) (Commission File Numb
September 2, 2021	EX-99.1	News & Media EXHIBIT 99.1 News & Media BioCorRx Announces Award of Approximately $3.5 Million NIDA Grant for the Clinical Trial of BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder On track to commence the first-in-human clinical trial for BICX104 ANAHEIM, CA, Sept. 01, 2021 (GLOBE NEWSWIRE) - via NewMediaWire - BioCorRx Inc. (OTCQB: BICX) (the ?Company?), a developer and prov
August 13, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54208 BioCorRx Inc. (Exac
May 17, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54208 BioCorRx Inc. (Exa
March 31, 2021	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 Commission File Number: 000-54208 10-K 1 bicx10k.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 Commission File Number: 000-54208 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 90-0967447 (State or other jurisdiction of incorpo
March 31, 2021	EX-4.3	Description of securities registered under Section 12 of the Exchange Act of 1934 EXHIBIT 4.3 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Set forth below is the description of the common stock, par value $0.001 per share (the ?Common Stock?) of BioCorRx Inc. (?we? or ?our?). The following description summarizes the most important terms of these securities. This summary does not purport to be complete and is qua
February 26, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 23, 2021 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or other jurisdiction of incorporation) (Commission File Numb
February 26, 2021	EX-10.1	Form of Subscription Agreement by and between BioCorRx Inc. and each of the Lucido and Galligan Trusts entered into on February 23, 2021 EX-10.1 2 bicxex101.htm FORM OF SUBSCRIPTION AGREEMENT EXHIBIT 10.1 BioCorRx Inc. 2390 East Orangewood Avenue Suite 500 Anaheim, California 92806 The undersigned understands that BioCorRx Inc., a corporation organized under the laws of Nevada (the “Company”), desired to sell shares of its common stock, par value $0.001 per share (the “Securities”), at a purchase price of $2.00 per share (the “Purc
February 22, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K 1 bicx8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 16, 2021 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or other jurisdiction of incorporat
February 22, 2021	EX-10.1	Form of Galligan Director Agreement EXHIBIT 10.1 DIRECTOR AGREEMENT This DIRECTOR AGREEMENT is made as of February [ ], 2021 (the ?Agreement?), by and between BioCorRx Inc., a Nevada corporation (the ?Company?), and Joseph J Galligan, an individual with an address of (the ?Director?). WHEREAS, the Company appointed the Director effective on February 17, 2021, and desires to enter into an agreement with the Director with respect to s
November 16, 2020	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54208 BioCorRx Inc. (Exact name
November 13, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2020 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
August 14, 2020	10-Q	Quarterly Report - FORM 10-Q 10-Q 1 bicx10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54208 B
May 15, 2020	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54208 BioCorRx Inc. (Exa
March 30, 2020	10-K	BICX / BioCorRx Inc. 10-K - Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2019 Commission File Number: 000-54208 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 90-0967447 (State or other jurisdiction of incorporation or organization) (IRS
March 3, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2020 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or Other Jurisdiction of Incorporation) (Commission File Numb
March 3, 2020	EX-99.1	March 2, 2020 EX-99.1 2 bicxex991.htm PRESS RELEASE EXHIBIT 99.1 March 2, 2020 BioCorRx Announces Senior Management Promotions Lourdes Felix Promoted to President Tom Welch Promoted to Executive Vice President ANAHEIM, CA, March 02, 2020 (GLOBE NEWSWIRE) - via NEWMEDIAWIRE - BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of advanced solutions in the treatment of substance use and related
January 30, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2020 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorpor
January 30, 2020	EX-99.1	BioCorRx Announces Award of $2.8 Million, the Second Tranche of a NIDA Grant for the Development of BICX102, a Sustained Release Naltrexone Implant for the Treatment of Opioid Use Disorder EXHIBIT 99.1 BioCorRx Announces Award of $2.8 Million, the Second Tranche of a NIDA Grant for the Development of BICX102, a Sustained Release Naltrexone Implant for the Treatment of Opioid Use Disorder ANAHEIM, CA, January 30, 2020 – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, has been awarded an additiona
December 9, 2019	RW	BICX / BioCorRx Inc. RW - - RW BioCorRx Inc. 2390 East Orangewood Avenue, Suite 575 Anaheim, California 92086 December 9, 2019 VIA EDGAR Gregory Dundas, Attorney Advisor Office of Telecommunications Division of Corporation Finance Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: BioCorRx Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-229690) Ladies and Gentlemen: Pursuant to
November 14, 2019	10-Q	BICX / BioCorRx Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54208 BioCorRx Inc.
November 14, 2019	EX-10.1	Second Amendment To Lease, dated July 11, 2019, by and between BioCorRx Inc. and Axis Campus Owner, LLC.* EXHIBIT 10.1
October 4, 2019	EX-10.2	Lock-Up Agreement, dated September 30, 2019 by and between BioCorRx Inc., and BICX Holding Company LLC EXHIBIT 10.2 Lock-Up Agreement This Lock-up Agreement, dated September 30, 2019, is by and between BioCorRx Inc., a Nevada corporation (the “Company”) and BICX Holding Company LLC (the “Investor”) (referred to collectively herein as the “Parties”). WHEREAS, the Company and the Investor entered into a Conversion Agreement dated September 30, 2019, pursuant to which the Company has agreed to issue t
October 4, 2019	EX-10.1	Conversion Agreement, dated September 30, 2019 by and between BioCorRx Inc., and BICX Holding Company LLC EXHIBIT 10.1 CONVERSION AGREEMENT Dated September 30, 2019 This Conversion Agreement, dated September 30, 2019 (this “Agreement”), is by and between BioCorRx Inc., a Nevada corporation (the “Company”) and BICX Holding Company LLC (the “Investor”) (referred to collectively herein as the “Parties”). WHEREAS, the Company and the Investor entered into a Senior Secured Convertible Note Purchase Agreeme
October 4, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 8-K 1 bicx8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2019 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or Other Jurisdiction (Commission (I.
August 14, 2019	10-Q	BICX / BioCorRx Inc. 10-Q - Quarterly Report - FORM 10-Q 10-Q 1 bicx10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number:
June 19, 2019	EX-16.1	Letter from Liggett & Webb, PA, dated June 19, 2019, to the Securities and Exchange Commission EXHIBIT 16.1 June 19, 2019 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated June 19, 2019 of BioCorRx, Inc. (the “Company”) and agree with the statements relating only to Liggett & Webb, P.A. contained therein. We have no basis to agree or disagree with other statements of the Company contained therein. /s/
June 19, 2019	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2019 BioCorRx Inc.
June 14, 2019	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 bicx8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2019 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or other jurisdiction of incorporation) (C
June 14, 2019	EX-10.2	Statement of Work 1 by and between BioCorRx Inc. and Charles River Laboratories Inc., dated May 30, 2019. EX-10.2 3 bicxex102.htm STATEMENT OF WORK 1 EXHIBIT 10.2 BioCorRx, Inc. May 30, 2019 This Statement of Work (“SOW”) is issued under and subject to the Master Services Agreement dated 24 May 2019, as amended, by and between Sponsor and Charles River (the “MSA”). If there is no such MSA in place, this SOW and each party’s obligations herein (including the performance of Services) shall be governed b
June 14, 2019	EX-10.1	Master Services Agreement by and between BioCorRx Inc. and Charles River Laboratories Inc., dated May 24, 2019. EX-10.1 2 bicxex101.htm MASTER SERVICES AGREEMENT EXHIBIT 10.1 MSA Page 1 of 15 BioCorRx, Inc. CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. MASTER SERVICES AGREEMENT THIS MASTER SERVICES AGREEMENT is made as of this 24
June 14, 2019	EX-10.3	Statement of Work 2 by and between BioCorRx Inc. and Charles River Laboratories Inc., dated May 30, 2019. EX-10.3 4 bicxex103.htm STATEMENT OF WORK 2 EXHIBIT 10.3 BioCorRx, Inc. May 30, 2019 This Statement of Work (“SOW”) is issued under and subject to the Master Services Agreement dated 24 May 2019, as amended, by and between Sponsor and Charles River (the “MSA”). If there is no such MSA in place, this SOW and each party’s obligations herein (including the performance of Services) shall be governed b
May 15, 2019	10-Q	BICX / BioCorRx Inc. 10-Q Quarterly Report FORM 10-Q 10-Q 1 bicx10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number:
April 17, 2019	SC 13D	BICX / BioCorRx Inc. / Galligan Joseph J - SC 13D Activist Investment SC 13D 1 bicxsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 BIOCORRX INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 09073C205 (CUSIP Number) 2390 East Orangewood Avenue, Suite 575 Anaheim, California 92806 (714) 462-4880 (Name, Address and Telephone Number
April 17, 2019	EX-1	Promissory Note EXHIBIT 1 PROMISSORY NOTE DATE: January 26, 2018 CITY: Anaheim STATE: California PRINCIPAL AMOUNT: 125,000 LENDER: Joe Galligan BORROWER: BioCorRx, Inc.
April 16, 2019	10-K	BICX / BioCorRx Inc. FORM 10-K (Annual Report) 10-K 1 bicx10k.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2018 Commission File Number: 000-54208 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 90-0967447 (State or other jurisdiction of incorpo
April 15, 2019	SC 13D	BICX / BioCorRx Inc. / Lucido Louis C. - SC 13D Activist Investment SC 13D 1 bicxsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 BIOCORRX INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 09073C205 (CUSIP Number) 2390 East Orangewood Avenue, Suite 575 Anaheim, California 92806 (714) 462-4880 (Name, Address and Telephone Number
April 3, 2019	EX-10.1	Subscription and Royalty Agreement by and between BioCorRx Inc. and Louis and Carolyn Lucido CRT LLC EX-10.1 2 bicxex101.htm SUBSCRIPTION AND ROYALTY AGREEMENT EXHIBIT 10.1 COVER SHEET WITH SUBSCRIPTION AND ROYALTY AGREEMENT INSTRUCTIONS Enclosed herewith are the documents necessary to subscribe for shares of common stock (the “Securities”) of BioCorRx Inc., a corporation organized under the laws of Nevada (the “Company”). Also enclosed herewith are the documents necessary to enter into a royalty
April 3, 2019	EX-10.2	Subscription and Royalty Agreement by and between BioCorRx Inc. and J and R Galligan Revocable Trust EX-10.2 3 bicxex102.htm SUBSCRIPTION AND ROYALTY AGREEMENT EXHIBIT 10.2 COVER SHEET WITH SUBSCRIPTION AND ROYALTY AGREEMENT INSTRUCTIONS Enclosed herewith are the documents necessary to subscribe for shares of common stock (the “Securities”) of BioCorRx Inc., a corporation organized under the laws of Nevada (the “Company”). Also enclosed herewith are the documents necessary to enter into a royalty
April 3, 2019	EX-99.1	BioCorRx Announces Above Market $6 Million Private Placement at $15 Per Share EX-99.1 4 bicxex991.htm PRESS RELEASE EXHIBIT 99.1 BioCorRx Announces Above Market $6 Million Private Placement at $15 Per Share APRIL 02, 2019 ANAHEIM, CA, April 02, 2019 (GLOBE NEWSWIRE) - via NEWMEDIAWIRE - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders, today announced the Company completed
April 3, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): March 28, 2019 BioCorRx Inc. (Exact Name of Registrant as Specified in Charter) Nevada 000-54208 90-0967447 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
April 1, 2019	NT 10-K	BICX / BioCorRx Inc. NT 10-K NT 10-K 1 bicxnt10k.htm NT 10-K x UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response………………………... 2.50 SEC FILE NUMBER 000-54208 CUSIP NUMBER (Check one): x Form 10-K o Form 20-F o Form 11-K ¨ Form 10-Q o Form 10-D o Form N-SAR o Form
March 8, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): March 4, 2019 BioCorRx Inc. (Exact Name of Registrant as Specified in Charter) Nevada 000-54209 90-0967447 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R
March 8, 2019	EX-10.1	Subscription Agreement dated February 22, 2019 EX-10.1 2 bicxex101.htm SUBSCRIPTION AGREEMENT EXHIBIT 10.1 COVER SHEET WITH SUBSCRIPTION INSTRUCTIONS Enclosed herewith are the documents necessary to subscribe for shares of common stock (the “Securities”) of BioCorRx Inc., a corporation organized under the laws of Nevada (the “Company”). Set forth herein are instructions for the execution of the enclosed documents. Each person considering subsc
March 7, 2019	EX-10.1	Form of Director Agreement. EXHIBIT 10.1 DIRECTOR AGREEMENT This DIRECTOR AGREEMENT is entered into as of March 1, 2019 (the “Agreement”), by and between BioCorRx Inc., a Nevada corporation (the “Company”), and , an individual with an address of (the “Director”). WHEREAS, the Company desires to continue with the services of the Director and Chairman of the Board, and desires to enter into an agreement with the Director with
March 7, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): March 1, 2019 BioCorRx Inc. (Exact Name of Registrant as Specified in Charter) Nevada 000-54208 90-0967447 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R
February 22, 2019	EX-10.1	Form of Director Agreement. EXHIBIT 10.1 DIRECTOR AGREEMENT This DIRECTOR AGREEMENT is made as of March 1, 2019 (the “Agreement”), by and between BioCorRx Inc., a Nevada corporation (the “Company”), and , an individual with an address of (the “Director”). WHEREAS, the Company appointed the Director effective on March 1, 2019, and desires to enter into an agreement with the Director with respect to such appointment; and WHERE
February 22, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): February 18, 2019 BioCorRx Inc. (Exact Name of Registrant as Specified in Charter) Nevada 000-54208 90-0967447 (State or Other Jurisdiction of Incorporation) (Commission File Number)
February 14, 2019	S-1	BICX / BioCorRx Inc. FORM S-1 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 BioCorRx Inc. (Exact name of Registrant as specified in its charter) Nevada 8093 90-0967447 (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identificati
January 23, 2019	EX-99.1	BioCorRx Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market EXHIBIT 99.1 BioCorRx Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market ANAHEIM, CA, January 23, 2019 – BioCorRx Inc. (OTCQB: BICX; BICXD) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today a reverse stock split of its shares of common stock at a ratio of 1-for-100. The reverse spli
January 23, 2019	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): January 18, 2019 BioCorRx Inc. (Exact Name of Registrant as Specified in Charter) Nevada 000-54209 90-0967447 (State or Other Jurisdiction of Incorporation) (Commission File Number) (
January 18, 2019	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): January 16, 2019 BioCorRx Inc. (Exact Name of Registrant as Specified in Charter) Nevada 000-54209 90-0967447 (State or Other Jurisdiction of Incorporation) (Commission File Number) (
January 18, 2019	EX-3.1	Certificate of Amendment to Articles of Incorporation, filed January 16, 2019. EXHIBIT 3.1
December 14, 2018	EX-10.2	Form of Promissory Note, dated December 12, 2018. EXHIBIT 10.2 THIS NOTE HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURIT
December 14, 2018	EX-10.3	Common Stock Purchase Warrant, dated December 12, 2018. EXHIBIT 10.3 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT OR APPLICABLE EXEMPTION OR SAFE HARBOR PROVISION. COMMON STOCK PURCHA
December 14, 2018	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): December 13, 2018 BioCorRx Inc. (Exact Name of Registrant as Specified in Charter) Nevada 000-54209 90-0967447 (State or Other Jurisdiction of Incorporation) (Commission File Number)
December 14, 2018	EX-10.1	Stock Purchase Agreement, dated December 12, 2018. EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of December 12, 2018, is entered into by and between BioCorRx Inc., a Nevada corporation, (the “Company”), and Vista Capital Investments, LLC (the “Buyer”). A. The Company and the Buyer are executing and delivering this Agreement in reliance upon the exemption from securities registration aff
November 21, 2018	EX-10.1	Stock Purchase Agreement, dated November 15, 2018. EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of November 15, 2018, is entered into by and between BioCorRx Inc., a Nevada corporation, (the “Company”), and LGH Investments, a Wyoming limited liability company (the “Buyer”). A. The Company and the Buyer are executing and delivering this Agreement in reliance upon the exemption from secur
November 21, 2018	EX-10.2	Form of Promissory Note, dated November 15, 2018. EXHIBIT 10.2 THIS NOTE HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURIT
November 21, 2018	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 8-K 1 bicx8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): November 15, 2018 BioCorRx Inc. (Exact Name of Registrant as Specified in Charter) Nevada 000-54209 90-0967447 (State or Other Jurisdiction of Incorporation)
November 21, 2018	EX-10.3	Common Stock Purchase Warrant, dated November 15, 2018. EXHIBIT 10.3 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT OR APPLICABLE EXEMPTION OR SAFE HARBOR PROVISION. COMMON STOCK PURCHA
November 14, 2018	10-Q	BICX / BioCorRx Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54208 BioCorRx Inc.
November 9, 2018	EX-99.1	BioCorRx Inc. Investor Presentation (November 2018) EXHIBIT 99.1
November 9, 2018	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 9, 2018 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or other jurisdiction of incorporation) (Commission File Numbe
September 7, 2018	CORRESP	BICX / BioCorRx Inc. CORRESP BioCorRx Inc. 2390 East Orangewood Avenue Suite 575 Anaheim, California 92086 September 7, 2018 VIA EDGAR U.S. Securities & Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: BioCorRx Inc. Registration Statement on Form S-1 File No. 333-227009 Ladies and Gentlemen: In accordance with Rule 461 of the Securities Act of 1933, as amended, BioCorRx Inc. (t
September 5, 2018	S-1/A	BICX / BioCorRx Inc. FORM S-1/A As filed with the Securities and Exchange Commission on September 5, 2018 Registration No.
August 24, 2018	EX-21.1	List of Subsidiaries. EXHIBIT 21.1 BioCorRx Inc. List of Subsidiaries Entity Name State of Incorporation Percentage Ownership BioCorRx Pharmaceuticals Inc. NV 75.8%
August 24, 2018	S-1	BICX / BioCorRx Inc. FORM S-1 S-1 1 bicxs1.htm FORM S-1 As filed with the Securities and Exchange Commission on August 24, 2018 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 8093 90-0967447 (State or Other Jurisdiction of Incorporation or Or
August 14, 2018	10-Q	BICX / BioCorRx Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54208 BioCorRx Inc. (Exac
June 15, 2018	EX-10.2	Executive Service Agreement by and between the Company and Brady Granier, dated June 13, 2018. EX-10.2 3 bicxex102.htm EXECUTIVE SERVICE AGREEMENT EXHIBIT 10.2 EXECUTIVE SERVICE AGREEMENT THIS EXECUTIVE SERVICE AGREEMENT dated as of June 13, 2018 (the “Agreement”) is by and between BioCorRx Inc., a Nevada corporation (the “Company”), and Soupface LLC [Brady Granier] (the “Executive”). WHEREAS, the Company is an addiction rehabilitation service company and developer of the BioCorRx Recovery
June 15, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits 8-K 1 bicx8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 13, 2018 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or other jurisdiction of incorporation)
June 15, 2018	EX-10.5	Director Compensation Agreement by and between the Company and Kent Emry, dated June 13, 2018 EXHIBIT 10.5 BioCorRx, Inc. Board of Directors Services Agreement This Board of Directors Services Agreement (the “Agreement”), dated June 13, 2018 is entered into between BioCorRx, Inc., a Nevada corporation (“the Company), and, Kent Emry an individual with a principal place of residence in Salem, Oregon (“Director”). WHEREAS, the Company desires to retain the services of Chairman of the Board of
June 15, 2018	EX-10.6	Director Compensation Agreement by and between the Company and Brady Granier dated June 13, 2018. EXHIBIT 10.6 BioCorRx, Inc. Board of Directors Services Agreement This Board of Directors Services Agreement (the “Agreement”), dated June 13, 2018 is entered into between BioCorRx, Inc., a Nevada corporation (“the Company), and Brady Granier an individual with a principal place of residence in Los Angeles, California (“Director”). WHEREAS, the Company desires to retain the services of Director fo
June 15, 2018	EX-10.4	Executive Service Agreement-Tom Welch (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed with the SEC on June 15, 2018) EXHIBIT 10.4 EXECUTIVE SERVICE AGREEMENT THIS EXECUTIVE SERVICE AGREEMENT dated as of June 13, 2018 (the “Agreement”) is by and between BioCorRx Inc., a Nevada corporation (the “Company”), and Tom Welch (the “Executive”). WHEREAS, the Company is an addiction rehabilitation service company and developer of the BioCorRx Recovery Program; WHEREAS, since February 26, 2015, Executive has been retained
June 15, 2018	EX-10.3	Executive Service Agreement by and between the Company and Lourdes Felix, dated June 13, 2018. EX-10.3 4 bicxex103.htm EXECUTIVE SERVICE AGREEMENT EXHIBIT 10.3 EXECUTIVE SERVICE AGREEMENT THIS EXECUTIVE SERVICE AGREEMENT dated as of June 13, 2018(the “Agreement”) is by and between BioCorRx Inc., a Nevada corporation (the “Company”), and Felix Financial Enterprise LLC [Lourdes Felix] (the “Executive”). WHEREAS, the Company is an addiction rehabilitation service company and developer of the B
June 15, 2018	EX-10.7	Director Compensation Agreement by and between the Company and Lourdes Felix, dated June 13, 2018. EXHIBIT 10.7 BioCorRx, Inc. Board of Directors Services Agreement This Board of Directors Services Agreement (the “Agreement”), dated June 13, 2018 is entered into between BioCorRx, Inc., a Nevada corporation (“the Company), and Lourdes Felix an individual with a principal place of residence in Rancho Santa Margarita, California (“Director”). WHEREAS, the Company desires to retain the services of
June 15, 2018	EX-10.1	Executive Management Bonus Plan effective June 13, 2018. EX-10.1 2 bicxex101.htm EXECUTIVE MANAGEMENT BONUS PLAN EXHIBIT 10.1 EXHIBIT A EXECUTIVE MANAGEMENT BONUS PLAN EFFECTIVE June 13, 2018 BIOCORRX INC. Purpose BioCorRx Inc.’s (the “Company”) executive compensation strategy is to pay a combination of base salary and bonuses that are competitive to market rates in the aggregate, and to reward executives for corporate financial performance and the achi
June 6, 2018	EX-10.2	Form of Warrant. EXHIBIT 10.2 EXHIBIT B THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR E
June 6, 2018	EX-10.1	Form of Subscription Agreement. EXHIBIT 10.1 COVER SHEET WITH SUBSCRIPTION INSTRUCTIONS Enclosed herewith are the documents necessary to subscribe for units of securities of BioCorRx Inc., a corporation organized under the laws of Nevada (the “Company”) with each unit consisting of: (i) one (1) share of the Company’s common stock, par value $0.001 per share; and (ii) one (1) warrant to purchase one (1) share of the Company’s com
June 6, 2018	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 16, 2018 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or other jurisdiction of incorporation) (Commission File Number) (
May 21, 2018	EX-10.1	Form of BioCorRx Inc. 2018 Equity Incentive Plan. EXHIBIT 10.1 BIOCORRX INC. 2018 EQUITY INCENTIVE PLAN I. Purpose; Eligibility. A. General Purpose. The name of this plan is the BioCorRx Inc. 2018 Equity Incentive Plan (the “Plan”). The purposes of the Plan are to (a) enable BioCorRx Inc., a Nevada corporation (the “Company”), to attract and retain the types of Employees, Consultants and Directors who will contribute to the Company’s long range s
May 21, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K 1 bicx8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2018 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or other jurisdiction of incorporation)
May 18, 2018	10-Q	BICX / BioCorRx Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54208 BioCorRx Inc. (Exa
May 16, 2018	EX-3.1	Certificate of Amendment to Articles of Incorporation, dated May 10, 2018. EXHIBIT 3.1 1 2
May 16, 2018	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 10, 2018 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or other jurisdiction of incorporation) (Commission File Number) (
May 15, 2018	NT 10-Q	BICX / BioCorRx Inc. NT 10-Q NT 10-Q 1 bicxnt10q.htm NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2018 Estimated average burden hours per response………………………... 2.50 SEC FILE NUMBER 000-54208 CUSIP NUMBER (Check one): ¨ Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-C
April 10, 2018	DEF 14C	BICX / BioCorRx Inc. DEF 14C DEF 14C 1 bicxdef14c.htm DEF 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ¨ Preliminary Information Statement ¨ Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2)) x Definitive Information Statement BioCo
April 5, 2018	10-K	BICX / BioCorRx Inc. FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2017 Commission File Number: 000-54208 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 90-0967447 (State or other jurisdiction of incorporation or organization) (IRS
April 2, 2018	NT 10-K	BICX / BioCorRx Inc. NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2018 Estimated average burden hours per response………………………... 2.50 SEC FILE NUMBER 000-54208 CUSIP NUMBER (Check one): x Form 10-K o Form 20-F o Form 11-K ¨ Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31
March 20, 2018	PRER14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14C INFORMATION (Amendment No. 1) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 PRER14C 1 bicxprer14c.htm PRER 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14C INFORMATION (Amendment No. 1) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Information Statement ¨ Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2)) ¨ Definitive Informa
March 20, 2018	CORRESP	BIOCORRX INC. 2390 EAST ORANGEWOOD AVENUE, SUITE 575 ANAHEIM, CA 92806 BIOCORRX INC. 2390 EAST ORANGEWOOD AVENUE, SUITE 575 ANAHEIM, CA 92806 March 20, 2018 Joshua Shainess U.S. Securities & Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: BioCorRx Inc. Preliminary Information Statement on Schedule 14C Filed February 27, 2018 File No. 000-54208 Dear Mr. Shainess: By letter dated March 8, 2018, the staff (the ?Staff,? ?you? or ?your?) of the U.S. Secu
March 1, 2018	EX-99.1	BioCorRx Inc. Investor Presentation (February 2018) bicxex991.htm EXHIBIT 99.1
March 1, 2018	8-K	Regulation FD Disclosure, Financial Statements and Exhibits bicx8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2018 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or other jurisdiction of incorporation) (Commissio
February 27, 2018	PRE 14C	BICX / BioCorRx Inc. PRE 14C bicxpre14c.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Information Statement ? Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement BioCorRx Inc. (Name of
February 20, 2018	EX-10.1	Investment Agreement by and between the Company and Northbridge Financial Inc., dated February 9, 2018. EX-10.1 2 bicxex101.htm INVESTMENT AGREEMENT EXHIBIT 10.1
February 20, 2018	EX-10.2	Registration Rights Agreement by and between the Company and Northbridge Financial Inc., dated February 9, 2018. bicxex102.htm EXHIBIT 10.2
February 20, 2018	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits bicx8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): February 9, 2018 BioCorRx Inc. (Exact name of registrant as specified in its charter) 000-54208 (Commission File Number) Nevada 90-0967447 (State or other jurisdiction of I
February 1, 2018	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant bicx8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): January 26, 2018 BioCorRx Inc. (Exact name of registrant as specified in its charter) 000-54209 (Commission File Number) Nevada 90-0967447 (State or other jurisdiction of I
February 1, 2018	EX-10.1	Form of Promissory Note. bicxex101.htm EXHIBIT 10.1 PROMISSORY NOTE DATE: January 26, 2018 CITY: Anaheim STATE: California PRINCIPAL AMOUNT: 125,000 LENDER: Lender Name Address City, State Zip BORROWER: BioCorRx, Inc. 2390 E. Orangewood Avenue, Suite 575 Anaheim, CA 92806 FOR VALUE RECEIVED, Borrower promises to pay to the order of Lender the sum of One Hundred Thousand Twenty-Five Dollars ($125,000), together with intere
January 23, 2018	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits bicx8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): January 17, 2018 BioCorRx Inc. (Exact name of registrant as specified in its charter) 000-54209 (Commission File Number) Nevada 90-0967447 (State or other jurisdiction of I
January 23, 2018	EX-10.1	Form of Subscription Agreement. bicxex101.htm EXHIBIT 10.1 COVER SHEET WITH SUBSCRIPTION INSTRUCTIONS Enclosed herewith are the documents necessary to subscribe for shares of common stock (the ?Securities?) of BioCorRx Inc., a corporation organized under the laws of Nevada (the ?Company?). Set forth herein are instructions for the execution of the enclosed documents. Each person considering subscribing for Securities should revi
December 14, 2017	EX-10.1	Distributor Agreement with CereCare, LLC, dated December 8, 2017. EXHIBIT 10.1 DISTRIBUTOR AGREEMENT This Distributor Agreement ("Agreement") is made and effective on December 8, 2017, by and between BioCorRx? Inc., having offices at 2390 E. Orangewood Avenue, Suite 575, Anaheim, CA 92806 ("Company") and CERECARE with its principal place of business at 6900 S. McCarran Blvd., #1010, Reno NV 89509, ("Distributor"). Recitals. Whereas, BioCorRx? has intellectual pr
December 14, 2017	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 bicx8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 10, 2017 BioCorRx Inc. (Exact Name of Registrant as Specified in Charter) Nevada 000-54208 90-0967447 (State or Other Jurisdiction of Incorporation)
November 14, 2017	10-Q	BICX / BioCorRx Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54208 BioCorRx Inc.
August 11, 2017	10-Q	BICX / BioCorRx Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54208 BioCorRx, Inc (Exac
July 6, 2017	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant bicx8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): June 29, 2017 BioCorRx Inc. (Exact name of registrant as specified in its charter) 000-54208 (Commission File Number) Nevada 90-0967447 (State or other jurisdiction of Inco
July 6, 2017	EX-10.1	Second Amendment to Senior Secured Convertible Note Purchase Agreement and Senior Secured Convertible Note by and between the Company and BICX Holding Company LLC, dated June 29, 2017. bicxex101.htm EXHIBIT 10.1 SECOND AMENDMENT TO SENIOR SECURED CONVERTIBLE NOTE PURCHASE AGREEMENT AND SENIOR SECURED CONVERTIBLE NOTE This Second Amendment to Senior Secured Convertible Note Purchase Agreement and Senior Secured Convertible Note is made this 29th day of June, 2017 (the ?Second Amendment?), by and among BioCorRx Inc., a Nevada corporation (the ?Company?), and BICX Holding Company L
May 15, 2017	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number: 000-54208 BioCorRx,
April 13, 2017	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2016 Commission File Number: 000-54208 BioCo UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2016 Commission File Number: 000-54208 BioCorRxÒ Inc. (Exact name of registrant as specified in its charter) Nevada 26-1972677 (State or other jurisdiction of incorporation or organization) (IRS
March 31, 2017	NT 10-K	BioCorRx NT 10-K bicxnt10k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2018 Estimated average burden hours per response?????????... 2.50 SEC FILE NUMBER 000-54208 CUSIP NUMBER (Check one): x Form 10-K o Form 20-F o Form 11-K ? Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ende
March 22, 2017	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits bicx8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 16, 2017 BioCorRx Inc. (Exact Name of Registrant as Specified in Charter) Nevada 000-54208 90-0967447 (State or Other Jurisdiction of Incorporation) (Commission File
March 22, 2017	EX-10.1	Settlement Agreement with Lucas Hoppel, dated March 16, 2017. bicxex101.htm EXHIBIT 10.1 SETTLEMENT AGREEMENT AND GENERAL RELEASE THIS SETTLEMENT AGREEMENT AND GENERAL RELEASE (this ?Agreement?), dated March 16, 2017 (the ?Effective Date?), is executed by and between BioCorRx, Inc., a Nevada corporation (the ?Company?) and Lucas Hoppel. The Company and Mr. Hoppel are each respectively referred to herein as a ?Party? and collectively as ?the Parties.? WHEREAS
March 22, 2017	EX-10.2	Settlement Agreement with Vista Capital Investments, LLC dated March 20, 2017. bicxex102.htm EXHIBIT 10.2 SETTLEMENT AGREEMENT AND GENERAL RELEASE THIS SETTLEMENT AGREEMENT AND GENERAL RELEASE (this ?Agreement?), dated March 20, 2017 (the ?Effective Date?), is executed by and between BioCorRx, Inc., a Nevada corporation (the ?Company?) and Vista Capital Investments, LLC (?Vista?). The Company and Vista are each respectively referred to herein as a ?Party? and collectively as
March 9, 2017	EX-10.1	First Amendment to Senior Secured Convertible Note Purchase Agreement by and between the Company and BICX Holding Company LLC, dated March 3, 2017. bicxex101.htm EXHIBIT 10.1 FIRST AMENDMENT TO SENIOR SECURED CONVERTIBLE NOTE PURCHASE AGREEMENT This First Amendment to Senior Secured Convertible Note Purchase Agreement is made this 3rd day of March, 2017 (the ?First Amendment?), by and among BioCorRx Inc., a Nevada corporation (the ?Company?), and BICX Holding Company LLC (the ?Purchaser?), the parties to that certain Senior Secured Convertibl
March 9, 2017	EX-10.2	Form of Subscription Agreement entered into between the Company and Investors during February and March 2017. bicxex102.htm EXHIBIT 10.2 COVER SHEET WITH SUBSCRIPTION INSTRUCTIONS Enclosed herewith are the documents necessary to subscribe for shares of common stock (the “Securities”) of BioCorRx Inc., a corporation organized under the laws of Nevada (the “Company”). Set forth herein are instructions for the execution of the enclosed documents. Each person considering subscribing for Securities should revi
March 9, 2017	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant bicx8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): February 13, 2017 BioCorRx Inc. (Exact name of registrant as specified in its charter) 000-54208 (Commission File Number) Nevada 90-0967447 (State or other jurisdiction of
February 8, 2017	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 bicx8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 8, 2017 BioCorRx Inc. (Exact name of registrant as specified in its charter) Nevada 000-54208 90-0967447 (State or other jurisdiction of incorporati
February 8, 2017	EX-99.1	BioCorRx Inc. Investor Presentation (February 2017) bicxex991.htm EXHIBIT 99.1
January 6, 2017	EX-10.1	Subscription Agreement with David de Csepel dated December 22, 2016. bicxex101.htm EXHIBIT 10.1
January 6, 2017	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits bicx8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): December 22, 2016 BioCorRx Inc. (Exact name of registrant as specified in its charter) 000-54209 (Commission File Number) Nevada 90-0967447 (State or other jurisdiction of
November 30, 2016	EX-4.1	Certificate of Designation, filed November 23, 2016. EX-4.1 2 bicxex41.htm CERTIFICATE OF DESIGNATION EXHIBIT 4.1 1 2 3 4 5
November 30, 2016	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits bicx8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): November 23, 2016 BioCorRx Inc. (Exact name of registrant as specified in its charter) 000-54209 (Commission File Number) Nevada 90-0967447 (State or other jurisdiction of
November 17, 2016	EX-32.01	CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 32.01 CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Brady Grainer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of BioCorRx Inc. on Form 10-Q for the quarter ended September 30, 2016 fully com
November 17, 2016	EX-31.02	CERTIFICATION EXHIBIT 31.02 CERTIFICATION I, Lourdes Felix, certify that: 1. I have reviewed this quarterly report on Form 10-Q of BioCorRx Inc..; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
November 17, 2016	EX-31.01	CERTIFICATION EXHIBIT 31.01 CERTIFICATION I, Brady Granier, certify that: 1. I have reviewed this quarterly report on Form 10-Q of BioCorRx Inc..; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
November 17, 2016	EX-32.02	CERTIFICATIONS OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 32.02 CERTIFICATIONS OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Lourdes Felix, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of BioCorRx Inc. on Form 10-Q for the quarter ended September 30, 2016 fully com
November 17, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2016 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 000-54208 BioCo
November 14, 2016	NT 10-Q	BioCorRx NT 10-Q bicxnt10q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2018 Estimated average burden hours per response?????????... 2.50 SEC FILE NUMBER 000-54208 CUSIP NUMBER (Check one): ? Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ende
October 27, 2016	EX-10.2	Form of Securities Purchase Agreement by and among the Company and the Investors, dated June 10, 2016. EX-10.2 3 bicxex102.htm FORM OF SECURITIES PURCHASE AGREEMENT EXHIBIT 10.2 1 2 3 4 5 6 7 8 9 10 11
October 27, 2016	EX-10.1	Form of 8% Convertible Promissory Note, dated October 20, 2016, issued by the Company bicxex101.htm EXHIBIT 10.1 1 2 3 4 5 6
October 27, 2016	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant bicx8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): October 21, 2016 BioCorRx Inc. (Exact name of registrant as specified in its charter) 000-54208 (Commission File Number) Nevada 26-0685980 (State or other jurisdiction of I
August 17, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2016 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 000-54208 BioCorRx I
August 15, 2016	NT 10-Q	BioCorRx NT 10-Q bicxnt10q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2018 Estimated average burden hours per response?????????... 2.50 SEC FILE NUMBER 000-54208 CUSIP NUMBER (Check one): ? Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ende
August 3, 2016	8-K	Development, Commercialization and License Agreement, dated July 28, 2016. bicx8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): July 28, 2016 BioCorRx Inc. (Exact name of registrant as specified in its charter) 000-54209 (Commission File Number) Nevada 26-0685980 (State or other jurisdiction of Inco
July 6, 2016	EX-3.1	Certificate of Amendment to the Articles of Incorporation, filed July 5, 2016. bicxex31.htm EXHIBIT 3.1 1 The Corporation is authorized to issue two classes of stock to be designated, respectively, "Common Stock" and "Preferred Stock". The total number of shares which the Corporation is authorized to issue is Five Hundred Twenty Five Million Six Hundred Thousand (525,600,000) shares. Five Hundred Twenty Five Million (525,000,000) shares shall be Common Stock, Par Value of $0
July 6, 2016	EX-4.1	Certificate of Designation, filed July 1, 2014, as corrected July 7, 2014. bicxex41.htm EXHIBIT 4.1 1 2 3 4
July 6, 2016	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits bicx8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): July 5, 2016 BioCorRx Inc. (Exact name of registrant as specified in its charter) 000-54209 (Commission File Number) Nevada 26-0685980 (State or other jurisdiction of Incor
July 6, 2016	EX-3.2	Amended and Restated Articles of Incorporation, filed May 7, 2014. bicxex32.htm EXHIBIT 3.2 1 2 3
June 20, 2016	EX-10.4	EXECUTIVE SERVICE AGREEMENT EX-10.4 5 bicxex104.htm EXECUTIVE SERVICE AGREEMENT EXHIBIT 10.4 EXECUTIVE SERVICE AGREEMENT THIS EXECUTIVE SERVICE AGREEMENT dated as of June 17, 2016 (the "Agreement") is by and between BioCorRx Inc., a Nevada corporation (the "Company"), and Brady Granier (the "Executive"). WHEREAS, the Company is an addiction rehabilitation service company and developer of the BioCorRx Recovery Program; WHEREA
June 20, 2016	EX-10.2	Senior Secured Convertible Note Purchase Agreement by and among the Company and BICX Holding Company LLC, dated June 10, 2016. bicxex102.htm EXHIBIT 10.2 NOTE PURCHASE AGREEMENT among BioCorRx Inc. and BICX HOLDING COMPANY LLC Dated as of June 10, 2016 Table of Contents ARTICLE 1 PURCHASE AND SALE OF THE NOTE 3 Section 1.1 Purchase and Sale of Note 3 Section 1.2 Reservation of Shares 3 Section 1.3 Purchase Price and Closing 3 Section 1.4 Increase in Authorized Shares 4 Section 1.5 Conversion Price 4 Section 1.6 Break-Up F
June 20, 2016	EX-10.6	EXECUTIVE SERVICE AGREEMENT EX-10.6 7 bicxex106.htm EXECUTIVE SERVICE AGREEMENT EXHIBIT 10.6 EXECUTIVE SERVICE AGREEMENT THIS EXECUTIVE SERVICE AGREEMENT dated as of June 17, 2016 (the "Agreement") is by and between BioCorRx Inc., a Nevada corporation (the "Company"), and Tom Welch (the "Executive"). WHEREAS, the Company is an addiction rehabilitation service company and developer of the BioCorRx Recovery Program; WHEREAS, s
June 20, 2016	EX-10.1	8% Senior Secured Convertible Promissory Note, dated June 10, 2016, issued by the Company to BICX Holding Company LLC. EX-10.1 2 bicxex101.htm SENIOR SECURED CONVERTIBLE PROMISSORY NOTE EXHIBIT 10.1 NEITHER THE OFFER NOR SALE OF THE SECURITIES REPRESENTED BY THIS NOTE HAS BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, (THE "1933 ACT"). THE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE 1933 ACT, OR AN OPINION OF
June 20, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 8-K 1 bicx8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): June 14, 2016 BioCorRx Inc. (Exact name of registrant as specified in its charter) 000-54208 (Commission File Number) Nevada 26-0685980 (State or other juris
June 20, 2016	EX-10.5	EXECUTIVE SERVICE AGREEMENT EX-10.5 6 bicxex105.htm EXECUTIVE SERVICE AGREEMENT EXHIBIT 10.5 EXECUTIVE SERVICE AGREEMENT THIS EXECUTIVE SERVICE AGREEMENT dated as of June 17, 2016 (the "Agreement") is by and between BioCorRx Inc., a Nevada corporation (the "Company"), and Felix Financial Enterprise LLC [Lourdes Felix] (the "Executive"). WHEREAS, the Company is an addiction rehabilitation service company and developer of the
June 20, 2016	EX-10.3	Security Agreement by and among the Company and BICX Holding Company LLC, dated June 10, 2016. bicxex103.htm EXHIBIT 10.3 SECURITY AGREEMENT THIS SECURITY AGREEMENT (this "Agreement") is made as of June 10, 2016 (the "Funding Date") by and among BIOCORRX INC., a Nevada corporation (the "Company" or "Debtor"); and BICX HOLDING COMPANY LLC (the "Secured Party") TO THAT CERTAIN NOTE PURCHASE AGREEMENT DATED AS OF JUNE 10, 2016 BETWEEN THE COMPANYAND THE SECURED PARTY (the "Purchase Agreement")
June 7, 2016	DEF 14C	BioCorRx DEF 14C bicxdef14c.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: o Preliminary Information Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) x Definitive Information Statement BioCorRx Inc. (Name o
May 24, 2016	PRER14C	BioCorRx PRER 14C PRER14C 1 bicxprer14c.htm PRER 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Information Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) o Definitive Information Statement B
May 23, 2016	PRE 14C	BioCorRx PRE 14C bicxpre14c.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Information Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) o Definitive Information Statement BioCorRx Inc. (Name o
May 23, 2016	EX-32.01	CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 32.01 CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Brady Grainer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of BioCorRx Inc. on Form 10-Q for the quarter ended March 31, 2016 fully complie
May 23, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2016 ¨ TRANSITION REPORT P UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2016 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 333-153381 BioCorRx
May 23, 2016	EX-32.02	CERTIFICATIONS OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 32.02 CERTIFICATIONS OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Lourdes Felix, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of BioCorRx Inc. on Form 10-Q for the quarter ended March 31, 2016 fully complie
May 23, 2016	EX-31.02	CERTIFICATION EXHIBIT 31.02 CERTIFICATION I, Lourdes Felix, certify that: 1. I have reviewed this quarterly report on Form 10-Q of BioCorRx Inc..; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
May 23, 2016	EX-31.01	CERTIFICATION EXHIBIT 31.01 CERTIFICATION I, Brady Granier, certify that: 1. I have reviewed this quarterly report on Form 10-Q of BioCorRx Inc..; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
May 20, 2016	EX-3.2	Amended and Restated Bylaws, effective as of May 13, 2016. bicxex32.htm EXHIBIT 3.2 1
May 20, 2016	8-K	BioCorRx FORM 8-K (Current Report/Significant Event) bicx8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): May 13, 2016 BioCorRx Inc. (Exact name of registrant as specified in its charter) 333-153381 (Commission File Number) Nevada 26-0685980 (State or other jurisdiction of Inco
May 13, 2016	NT 10-Q	BioCorRx NT 10-Q bicxnt10q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2018 Estimated average burden hours per response?????????... 2.50 SEC FILE NUMBER 000-54208 CUSIP NUMBER (Check one): ? Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ende
April 18, 2016	EX-10.1	Termination of Asset Purchase Agreement, dated April 15, 2016 (incorporated by reference to Form 8-K filed on April 18, 2016) bicxex101.htm EXHIBIT 10.1 TERMINATION OF ASSET PURCHASE AGREEMENT WHEREAS the parties herein previously entered into and executed an Asset Purchase Agreement "AGREEMENT" between TRINITY COMPOUND SOLUTIONS, LLC, and BIOCORRX, Inc., "BIO" on or about June 30, 2015. It is their mutual desire to terminate Agreement in its entirety and return to their respective status that each occupied prior to AGRE
April 18, 2016	8-K	BioCorRx FORM 8-K (Current Report/Significant Event) bicx8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): April 15, 2016 BioCorRx Inc. (Exact name of registrant as specified in its charter) 333-153381 (Commission File Number) Nevada 26-0685980 (State or other jurisdiction of In
April 14, 2016	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2015 Commission File Number: 333-153381 BioC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2015 Commission File Number: 333-153381 BioCorRxÒ Inc. (Exact name of registrant as specified in its charter) Nevada 26-1972677 (State or other jurisdiction of incorporation or organization) (IR
March 30, 2016	NT 10-K	BioCorRx NT 10-K bicxnt10k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2018 Estimated average burden hours per response?????????... 2.50 SEC FILE NUMBER 000-54208 CUSIP NUMBER (Check one): x Form 10-K o Form 20-F o Form 11-K ? Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ende
March 18, 2016	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits bicx8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): March 15, 2016 BioCorRx Inc. (Exact name of registrant as specified in its charter) 333-153381 (Commission File Number) Nevada 26-0685980 (State or other jurisdiction of In
March 18, 2016	EX-10.1	Secured Promissory Note, dated March 15, 2016 (incorporated by reference to Form 8-K filed on March 18, 2016) bicxex101.htm EXHIBIT 10.1 SECURED PROMISSORY NOTE $360,000 March 15, 2016 Orange, California FOR VALUE RECEIVED, BIOCORRX INC., a Nevada corporation ("Borrower"), hereby unconditionally promises to pay to the order of DIRECT EDGE SCREENWORKS, INC., a California corporation, or its assigns ("Holder"), in lawful money of the United States of America and in immediately available funds, the principal
February 18, 2016	EX-10.1	Supply and Distribution Agreement, dated February 12, 2016 (incorporated by reference to Form 8-K filed on February 18, 2016) bicxex101.htm
February 18, 2016	8-K	BioCorRx FORM 8-K (Current Report/Significant Event) bicx8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): February 12, 2016 BioCorRx Inc. (Exact name of registrant as specified in its charter) 333-153381 (Commission File Number) Nevada 26-0685980 (State or other jurisdiction of
February 16, 2016	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits bicx8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): February 9, 2016 BioCorRx Inc. (Exact name of registrant as specified in its charter) 333-153381 (Commission File Number) Nevada 26-0685980 (State or other jurisdiction of
February 16, 2016	EX-10.1	Supply and Distribution Agreement, dated February 9, 2016 (incorporated by reference to Form 8-K filed on February 16, 2016) bicxex101.htm EXHIBIT 10.1
February 10, 2016	EX-4.1	10% Convertible Promissory Note, dated February 1, 2016, issued to Iconic Holdings, LLC EX-4.1 2 bicxex41.htm PROMISSORY NOTE EXHIBIT 4.1
February 10, 2016	8-K	BioCorRx FORM 8-K (Current Report/Significant Event) bicx8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): February 1, 2016 BioCorRx Inc. (Exact name of registrant as specified in its charter) 333-153381 (Commission File Number) Nevada 26-0685980 (State or other jurisdiction of
February 10, 2016	EX-4.2	Amended Agreement to Note, dated February 5, 2016, by and between BioCorRx Inc. and Iconic Holdings, LLC bicxex42.htm EXHIBIT 4.2 1 2
January 29, 2016	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits bicx8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported):January 26, 2016 BioCorRx Inc. (Exact name of registrant as specified in its charter) 333-153381 (Commission File Number) Nevada 26-0685980 (State or other jurisdiction of I
January 29, 2016	EX-10.1	Asset Purchase Agreement by and between the Company and Well Advised, signed January 26, 2016. bicxex101.htm EXHIBIT 10.1 1 2 3 4
January 26, 2016	EX-10.1	Supply and Distribution Agreement, dated January 21, 2016 (incorporated by reference to Form 8-K filed on January 26, 2016) bicxex101.htm EXHIBIT 10.1
January 26, 2016	EX-10.2	EX-10.2 bicxex102.htm EXHIBIT 10.2
January 26, 2016	8-K	BioCorRx FORM 8-K (Current Report/Significant Event) bicx8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): January 20, 2016 BioCorRx Inc. (Exact name of registrant as specified in its charter) 333-153381 (Commission File Number) Nevada 26-0685980 (State or other jurisdiction of
January 12, 2016	EX-10.1	Supply and Distribution Agreement, dated January 8, 2016 (incorporated by reference to Form 8-K filed on January 12, 2016) EX-10.1 2 bicxex101.htm SUPPLY AND DISTRIBUTION AGREEMENT EXHIBIT 10.1 1 2 3 4 5 6 7 8 9 10 11 12 13 14
January 12, 2016	8-K	BioCorRx FORM 8-K (Current Report/Significant Event) bicx8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): January 8, 2016 BioCorRx Inc. (Exact name of registrant as specified in its charter) 333-153381 (Commission File Number) Nevada 26-0685980 (State or other jurisdiction of I
January 7, 2016	8-K	BioCorRx FORM 8-K (Current Report/Significant Event) bicx8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): January 4, 2016 BioCorRx Inc. (Exact name of registrant as specified in its charter) 333-153381 (Commission File Number) Nevada 26-0685980 (State or other jurisdiction of I
January 7, 2016	EX-10.1	Supply and Distribution Agreement, dated January 4, 2016 (incorporated by reference to Form 8-K filed on January 7, 2016) bicxex101.htm EXHIBIT 10.1
December 30, 2015	EX-10.1	Supply and Distribution Agreement, dated December 28, 2015 (incorporated by reference to Form 8-K filed on December 30, 2015) bicxex101.htm EXHIBIT 10.1
December 30, 2015	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 bicx8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): December 28, 2015 BioCorRx Inc. (Exact name of registrant as specified in its charter) 333-153381 (Commission File Number) Nevada 26-0685980 (State or other
December 21, 2015	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): December 15, 2015 BioCorRx Inc. (Exact name of registrant as specified in its charter) 333-153381 (Commission File Number) Nevada 26-0685980 (State or other jurisdiction of Incorporat
December 21, 2015	EX-10.1	Supply and Distribution Agreement, dated December 15, 2015 (incorporated by reference to Form 8-K filed on December 21, 2015) bicxex101.htm EXHIBIT 10.1
December 17, 2015	EX-10.1	Royalty Agreement by and between BioCorRx Inc. and Alpine Creek Capital Partners LLC bicxex101.htm EXHIBIT 10.1
December 17, 2015	8-K	BioCorRx FORM 8-K (Current Report/Significant Event) bicx8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): December 10, 2015 BioCorRx Inc. (Exact name of registrant as specified in its charter) 333-153381 (Commission File Number) Nevada 26-0685980 (State or other jurisdiction of

BICX / BioCorRx Inc. - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

Grundläggande statistik

SEC Filings

SEC Filings (Chronological Order)